GKB Ophthalmics Quarterly Results for Trading Insights
In Mar 2026, GKB Ophthalmics (GKB) reported revenue ₹31 Cr and net profit ₹1 Cr. Also explore GKB share price charts to track price trends across different timeframes.
GKB Quarterly Results — Revenue, Profit & EPS Highlights
GKB Ophthalmics latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit GKB Ophthalmics screener.
- Revenue of ₹31 Cr in Mar 2026 (+0.0% vs Sept 2025, +0.0% vs Mar 2025)
- Net Profit of ₹1 Cr in Mar 2026 (-50.0% vs Sept 2025, +125.0% vs Mar 2025)
- EBITDA of ₹2 Cr in Mar 2026 (-33.3% vs Sept 2025)
- Operating Margin of 5.0% in Mar 2026 (-5.0pp vs Sept 2025)
- Earnings Per Share of ₹0.38 in Mar 2026 (-88.0% vs Sept 2025)
GKB Ophthalmics Quarterly Results — Revenue, EBITDA, Net Profit & EPS
GKB quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 31 | 31 | 31 | 33 | 58 | - | - |
| Net Profit (₹ Cr) | 1 | 2 | -4 | -1 | 1 | - | - |
| EBITDA (₹ Cr) | 2 | 3 | -3 | 1 | 2 | - | - |
| EPS (₹) | 0.38 | 3.17 | -7.03 | -2.02 | 0.08 | - | - |
| Operating Margin (%) | 5.0% | 10.0% | -9.0% | 2.0% | 2.0% | - | - |
GKB Share Price Trend — 1-Year Movement Across Quarterly Results
GKB Ophthalmics 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Compare with GKB Ophthalmics valuation methods to assess whether the stock is under or overvalued.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
GKB vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
GKB Ophthalmics latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹441,069.70 Cr | 1862.8 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 164.8 |
|
Divis Laboratories
Mar 2026 |
₹180,186.80 Cr | 6713.5 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 237.1 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹152,449.36 Cr | 4516.2 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 392.4 |
|
Cipla
Mar 2026 |
₹116,150.78 Cr | 1440.1 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 209.6 |
|
Dr Reddys Laborator…
Mar 2026 |
₹110,873.98 Cr | 1350.5 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 509.6 |
All amounts in ₹ Crores